Oncolytics Biotech Inc T.ONC

15$ US Target reiterated today as well

[askretka]

In a report released today,Patrick Trucchiofrom H.C. Wainwright maintained aBuyrating on Oncolytics Biotech (ONCYResearch Report), with a price target of$15.00. The companys shares closed last Wednesday at $2.83. Cheers!

[canadafan]

And that is $15 USD  closer to $ 18ps CDN. few appreciate first our English major working on the word modest...lol Panc cancer is a near death sentence. Very little to zero treatment. Modest effeciacy is GREAT. don't believe me look up a product called Jubilia. it is approved for toe nail fungus. At best it shows 40% efficacy. That is less then 1/2 and not even modest! Lol yet

[JohnnyYeg]

Getting so annoyed with people who say "oh but I'm long on ONC" after exploiting any opportunity to bash or create an air of disillusionment. But thankfully with all bull boards out there you are given the functionality to block them. Cannot. Be. Bothered. With. Negativity. Which is why I have left Yahoo Finance altogether. Miss only a few posters on there.

[Actuarial]

Hey Johnny, you are too emotional on this case. We need to be objective on each clinical trial results. If it contains something like "statistical significant", I know it is promising. However, it says "modest" and 33% in the paper, I am not impressed. I will keep holding my shares waiting for the CAR-T cell. And obviously, it will be a long wait. GLTA.

[HCallahann44]

Actuarial---you are forgetting that these study patients are on their last legs with immune systems destroyed by chemo and other modern medicine garbage...who knows what pela could do in someone who doesn't start with chemo....since it primes the immune system...not much immune system left in panc patients..

[Actuarial]

Hcallahann44 - What you said make sense to me. However,it leads to another issue,why don't we do this trial?It cost money and time. I have more hope on CAR-T cell. That is 100%cure. The management should put more resources into this project.imho

[Normandt1965]

I fully agree with you Johnny. I noticed they start slowly but constantly find a negative way to report any news. I would not be surprised they moved from yahoo to stockhouse forum.....since they are not enough popular on yahoo.

[canadafan]

With the $15 usd one yr target being reinforced, and favourable write up from Doug Mm ( RBC capital) ...They still predict PH3 announcement before end of this year. that would mean a partnership & emediate SP doubling, at that announcement. going into long weekend TSX is closed Monday, but NAS is open. With Panc cancer follow up June 5 Th, and 2-3 other catalysts expected next 2-3 months

[JohnnyYeg]

Thank you Brad. I'm done with Actuarial.

[Actuarial]

No need to get mad, Johnny. It is only a discussion on what it exactly means when we see something "modest" and "33% in ASCO vs. announcement today 42%". I have higher expectation on CAR-T cell, where 100% is true pormising.

[Capitalista]

I'm with Actuarial on this one.  One-year survival for PDAC under all existing treatments is around 28%.  The ASCO abstract (written before all results were in) stated that disease control was achieved in 33% of patients.  Not sure how long their period of observation was in this study, but 33% is a "modest" improvement over 28%.   I'm not bashing

[Actuarial]

Exactly, Capitalista. I never say that pelareorep doesn't have potential. It just need a little bit fine tune - combine with the right treatment, where I see CAR-T cell be the right one. I am still very long with ONC but only not impressed by today's release.

[Capitalista]

There are several PDAC CAR-T cell trials on at the moment - see the link below.  Maybe ONC can do a joint trial once they get to Phase 2.   https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7724172/